navitoclax (ABT 263) / AbbVie  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
navitoclax (ABT 263) / AbbVie
TRANSFORM-1, NCT04472598 / 2020-000097-15: Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

Hourglass Jan 2024 - Dec 2024 : Approval for 1L myelofibrosis (based on TRANSFORM-1 trial)
Jan 2023 - Dec 2023: Data readout from TRANSFORM-1 trial in combination with Jakafi oral for myelofibrosis
Completed
3
252
Europe, Canada, Japan, US, RoW
Navitoclax, ABT-263, Ruxolitinib, Placebo for Navitoclax
AbbVie
Myelofibrosis (MF)
04/23
01/25
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Hourglass Jan 2024 - Dec 2024 : Regulatory submission for r/r myelofibrosis (based on TRANSFORM-2 trial)
Hourglass Jan 2024 - Dec 2024 : Data readout from P3 TRANSFORM-2 trial in combination with ruxolitinib for r/r myelofibrosis
Active, not recruiting
3
330
Europe, Canada, Japan, US, RoW
Navitoclax, Ruxolitinib, Best Available Therapy (BAT)
AbbVie
Myelofibrosis (MF)
01/25
12/26

Download Options